Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Melanoma 4 Endometrial Neoplasms 4 Breast Neoplasms 4 Uterine Cervical Neoplasms 3 Neoplasm Metastasis 3 Squamous Cell Carcinoma of Head and Neck 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Rhabdomyosarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Multiple Myeloma 1 Hodgkin Disease 1 Hepatoblastoma 1 Glioblastoma 1 Fibrolamellar hepatocellular carcinoma 1 Fallopian Tube Neoplasms 1 Ependymoma 1

Interventions

Dexamethasone 18 Cyclophosphamide 16 fludarabine 11 pomalidomide 9 pembrolizumab 9 carfilzomib 9 daratumumab 7 Rituximab 7 Lenalidomide 7 Calcium Dobesilate 7 fludarabine phosphate 6 Cisplatin 6 Bortezomib 6 Gemcitabine 5 venetoclax 4 elotuzumab 4 isatuximab 3 Vincristine 3 Radiotherapy 3 Prednisone 3 Letrozole 3 Etoposide 3 Doxorubicin 3 Cytarabine 3 tisagenlecleucel 2 selinexor 2 ruxolitinib 2 palbociclib 2 ixazomib 2 dexamethasone 21-phosphate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × dostarlimab × Clear all

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡